Avicenna Biosciences Inc., 101 W. Chapel Hill Street, Suite 210, Durham, North Carolina 27001, United States.
Schrödinger, Inc., 120 West 45th Street, New York, New York 10036, United States.
J Chem Inf Model. 2024 May 13;64(9):3812-3825. doi: 10.1021/acs.jcim.4c00071. Epub 2024 Apr 23.
In the realm of medicinal chemistry, the primary objective is to swiftly optimize a multitude of chemical properties of a set of compounds to yield a clinical candidate poised for clinical trials. In recent years, two computational techniques, machine learning (ML) and physics-based methods, have evolved substantially and are now frequently incorporated into the medicinal chemist's toolbox to enhance the efficiency of both hit optimization and candidate design. Both computational methods come with their own set of limitations, and they are often used independently of each other. ML's capability to screen extensive compound libraries expediently is tempered by its reliance on quality data, which can be scarce especially during early-stage optimization. Contrarily, physics-based approaches like free energy perturbation (FEP) are frequently constrained by low throughput and high cost by comparison; however, physics-based methods are capable of making highly accurate binding affinity predictions. In this study, we harnessed the strength of FEP to overcome data paucity in ML by generating virtual activity data sets which then inform the training of algorithms. Here, we show that ML algorithms trained with an FEP-augmented data set could achieve comparable predictive accuracy to data sets trained on experimental data from biological assays. Throughout the paper, we emphasize key mechanistic considerations that must be taken into account when aiming to augment data sets and lay the groundwork for successful implementation. Ultimately, the study advocates for the synergy of physics-based methods and ML to expedite the lead optimization process. We believe that the physics-based augmentation of ML will significantly benefit drug discovery, as these techniques continue to evolve.
在药物化学领域,主要目标是快速优化一组化合物的多种化学性质,以产生准备进行临床试验的临床候选药物。近年来,两种计算技术——机器学习 (ML) 和基于物理的方法——有了显著的发展,现在经常被纳入药物化学家的工具包中,以提高命中优化和候选物设计的效率。这两种计算方法都有其自身的局限性,而且它们通常是相互独立使用的。ML 能够快速筛选大量化合物库的能力受到其对高质量数据的依赖的限制,尤其是在早期优化阶段,高质量数据可能很稀缺。相比之下,自由能微扰 (FEP) 等基于物理的方法通常受到通量低和成本高的限制;然而,基于物理的方法能够进行高度准确的结合亲和力预测。在这项研究中,我们利用 FEP 的优势来克服 ML 中的数据匮乏问题,通过生成虚拟活性数据集来为算法的训练提供信息。在这里,我们表明,使用 FEP 增强数据集训练的 ML 算法可以达到与使用生物测定实验数据训练的数据集相当的预测准确性。在整篇论文中,我们强调了在目标是增强数据集时必须考虑的关键机制性考虑因素,并为成功实施奠定了基础。最终,该研究提倡将基于物理的方法和 ML 相结合,以加快先导优化过程。我们相信,基于物理的 ML 增强将极大地有益于药物发现,因为这些技术将继续发展。
J Chem Inf Model. 2024-5-13
Int J Mol Sci. 2024-11-14
Annu Rev Biochem. 2024-8
J Chem Inf Model. 2017-12-15
Methods Mol Biol. 2019
J Med Chem. 2021-12-23
ACS Med Chem Lett. 2025-4-29
Future Med Chem. 2025-3
J Chem Theory Comput. 2022-10-11
Cancers (Basel). 2020-6-7
Drug Discov Today. 2020-6
Nature. 2020-3-16
Front Chem. 2020-1-8